MACE, VTE Risks Not Increased With JAK inhibitors: Study : c

In studies with an average follow-up of 16 weeks, there was no significant increase in MACE or VTE rates in people with dermatoses treated with JAK-STAT inhibitors.

Related Keywords

Ireland , Washington , United States , Randwick , New South Wales , Australia , Adam Friedman , Eli Lily , Drug Administration , University Of New South Wales , George Washington University , Pfizer , Patrick Ireland , Dermatological Conditions , Thromboembolism , Cv Risk , Cardiovascular Risk , V Risk Factors , Cardiovascular Risk Factors , Cardiovascular Risk Management , Stroke Cerebrovascular Accident Cva , Dermatoses , Skin Disorders , Skin Diseases , Meta Analysis , Psoriasis , Pulmonary Embolism Pe Embolus , Dermatitis , Venous Thromboembolism ,